feedback

Faculty

Mark Stolar
Mark Stolar, MD

Associate Professor of Clinical Medicine
Internal Medicine and Geriatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL

Davida F. Kruger
Davida F. Kruger, MSN, APN-BC, BC-ADM

Certified Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes,
Bone and Mineral Disease
Detroit, MI

Philip Raskin
Philip Raskin, MD, FACP, FACE, CDE

Professor of Medicine
Clifton and Betsy Robinson Chair
in Biomedical Research
University of Texas Southwestern
Medical Center
Dallas, TX

Activity Planners

Iwona Misiuta, PhD, MHA
Clinical Content Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of Continuing Medical Education
Med-IQ
Baltimore, MD

Sponsored By

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 0.5 AMA PRA Category 1 Credit
Release Date: May 24, 2016
Expiration Date: May 23, 2017
Estimated Time to Complete Activity: 30 minutes
Registration Required: No
Fee for Activity: No

Learning Objectives

Upon completion, participants should be able to:

  • Describe the differences in the pharmacologic properties of GLP-1 receptor agonists and the importance of those differences as they relate to combination therapy for T2DM
  • Integrate clinical evidence to determine when basal insulin/GLP-1 receptor agonist combination therapy is an appropriate strategy

Target Audience

This activity is intended for endocrinologists, family practice physicians, and internal medicine physicians.

Statement of Educational Need

Over the past 10 years, substantial scientific advances have resulted in the development of new medications for managing hyperglycemia and improvements in traditional treatments. Recent clinical data have shown the potential power of combining basal insulin and a GLP-1 receptor agonist, which maximizes the efficacy of each agent while minimizing side effects that limit the use of each agent separately. These new data, however, may not be translating optimally into clinical practice as persistent barriers related to delayed insulin initiation and hesitation to initiate GLP-1 receptor agonists altogether still exist. In addition, self-management plays a key role in diabetes care, and any tools that can be developed to help empower patients to be successful stewards of their own health are particularly helpful in this patient population. This Webcast will help meet these needs by reviewing the pharmacokinetic and pharmacodynamic properties of GLP-1 receptor agonist that contribute to the effectiveness of combining a GLP-1 receptor agonist with basal insulin to achieve better glycemic control.

Accreditation Statement

Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Others: Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit

The evaluation, attestation, and post-test can be accessed by continuing on with this activity after the video has ended.

Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Davida F. Kruger, MSN, APN-BC, BC-ADM
Consulting fees/advisory boards: Abbott Laboratories, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi-aventis U.S. Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Dexcom, Inc.
Other (Speakers Bureau): Animas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Novo Nordisk, Valeritas, Inc.

Philip Raskin, MD, FACP, FACE, CDE
Consulting fees/advisory boards: Boston Therapeutics, Inc., GlaxoSmithKline

Mark Stolar, MD
Consulting fees/advisory boards: AstraZeneca, Sanofi-aventis U.S. Inc., Takeda Pharmaceuticals North America, Inc.
Fees received for promotional/non-CME activities: AstraZeneca, Sanofi-aventis U.S. Inc., Takeda Pharmaceuticals North America, Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content

Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information

For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

ADA Statement

Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality

Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: http://www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi US.

Copyright

© 2016 Med-IQ®. All rights reserved.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.